| Autor: |
Domenech, E. Domingo, Climent, F., Barca, E. Gonzalez, de Lama, E., Lopez‐Pereira, P., Martinez‐Iniesta, M., Calaf, M., Oliveira, A., Montaner, C., Aguilera, C., Banda, E. de la, Villanueva, A., Sureda, A., Farre, L. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p551-552, 2p |
| Abstrakt: |
B Conclusions: b To our knowledge, these are one of the first orthotopic PDX lymphoma models generated, that can allow us to expand patients' refractory tumors in order to extensively study molecular features of them and target effective drug profiles. Patient-derived orthotopic xenografts (PDOXs), in which a human tumor biopsy is implanted in an immunodeficient mice in the same organ as the tumor is grown in the patient, are the most advanced in vivotumor preclinical models, as they reproduce better patient tumor behavior and therapeutic responses. B Introduction: b Novel targeted therapies have improved the treatment of relapse/refractory lymphomas, although overcoming therapy resistance is still a main clinical challenge and an overriding priority for patients and treating physicians. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text